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SUMMARY
Instrumental variable (IV) methods are widely used to adjust for the bias in estimating treat-
ment effects caused by unmeasured confounders in observational studies. In this manuscript,
we provide empirical and theoretical evidence that the IV methods may result in biased treat-
ment effects if applied on a data set in which subjects are preselected based on their received
treatments. We frame this as a selection bias problem and propose a procedure that identifies
the treatment effect of interest as a function of a vector of sensitivity parameters. We also list
assumptions under which analyzing the preselected data does not lead to a biased treatment ef-
fect estimate. The performance of the proposed method is examined using simulation studies.
We applied our method on The Health Improvement Network (THIN) database to estimate the
comparative effect of metformin and sulfonylureas on weight gain among diabetic patients.
Some key words: Causal inference, Instrumental Variables, Selection Bias, Sensitivity Analysis.
1. INTRODUCTION
Confounder adjustment is critical in the estimation of treatment effect in observational studies.
In practice, however, there is no guarantee that all the confounders (i.e., baseline variables that
affect both the treatment and outcome) have been measured. These unmeasured confounders can
bias the treatment effect estimation.
Instrumental variable (IV) methods are designed to adjust for the bias caused by unmeasured
confounders in estimating a difference measure of effect such as the risk difference. IVs are pre-
dictors of treatment allocation that are independent of unmeasured confounders and do not have
a direct effect on the outcome (i.e., only affect the outcome through affecting the treatment).
Intuitively, the IV method seeks to extract variation in treatment that is free of unmeasured con-
founders and uses this variation to estimate the treatment effect. For more information on IV
methods, see Angrist et al. (1996), Newhouse and McClellan (1998), Greenland (2000), Herna´n
and Robins (2006), Cheng et al. (2009a), Baiocchi et al. (2014) and Imbens (2014). This paper
is motivated by provider preference IV (PP IV) which is commonly used as an IV in health stud-
ies. PP IV utilizes the natural variation in medical practices to construct an IV. For example, in
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2studying the effect of cyclooxygenase-2 (COX-2) inhibitors vs. nonselective nonsteroidal anti-
inflammatory drugs (nonselective NSAIDs) on gastrointestinal complications Brookhart et al.
(2006) used whether a patient’s physician last prescription for a patient prescribed a nonsteroidal
anti-inflammatory drug (NSAID) was for a Cox-2 inhibitor or a nonselective NSAID as an IV for
whether the patient was prescribed a Cox-2 inhibitor or a nonselective NSAID. Other examples
of PP IV can be found in Brooks et al. (2003) and Brookhart and Schneeweiss (2007).
For a binary IV and binary treatment, Angrist et al. (1996) proposed a nonparametric estimator
which identifies the treatment effect among subjects who would take the treatment if encouraged
to do so by the IV and not take the treatment if not encouraged to do so by the IV (compliers).
This estimator is equivalent to a 2 stage least square (2SLS) estimator where at the first stage the
treatment is regressed on IV and at the second stage the outcome is regressed on fitted values of
the first stage regression (i.e., predicted value of the treatment variable given the IV). The coef-
ficient of the independent variable of the second stage regression is equivalent to the estimator
proposed by Angrist et al. (1996). The 2SLS estimator is also called the Wald estimator after
Wald (1940). More efficient versions of the 2SLS estimator has been developed by Imbens and
Rubin (1997b), Imbens and Rubin (1997a) and Cheng et al. (2009b).
Although treatment effect estimation using IV approaches for binary treatments is straight-
forward, it is challenging when there are more than two treatment arms. In fact, Cheng and
Small (2006) shows that the treatment effects are not point identifiable and proposes bounds on
treatment effects using method of moments. Long et al. (2010) studies the same problem and
proposes a Bayesian approach for finding credibility intervals for the identification region.
Sometimes investigators are interested in comparing the effect of two treatments while the data
consist of more than two treatment options for patients. In this situation a common approach is
to select patients who are assigned to the treatments of interest and perform the standard IV
approach for binary treatment and IV to estimate the treatment effect (Hadley et al., 2003; Basu
et al., 2007; Hadley et al., 2010; Suh et al., 2012; Chen et al., 2014).
The objective of this manuscript is to provide empirical and theoretical evidence that, in gen-
eral, excluding patients based on their assigned treatment can result in selection bias. This prob-
lem has also been discussed in an independent work by Swanson (2014a), Swanson (2014b),
and Swanson et al. (2015). In the current manuscript, we formalize the mechanism of this selec-
tion bias within a principal stratification framework and provide a procedure that identifies the
treatment effect of interest as a function of a vector of sensitivity parameters. Specifically, the
sensitivity parameters are used to estimate the probability of being assigned to one of the treat-
ments of interest as a function of the observed outcome and the IV value (Gilbert et al., 2003).
We also list assumptions under which selecting patients based on their received treatment does
not lead to a biased treatment effect estimate.
The manuscript is organized as follows. Section 2 provides the setup and defines the causal
estimand. It also lists the required assumptions for our procedure. In Section 3, we discuss the
selection bias issue and present the proposed sensitivity analysis method. We report on the results
of a simulation study in Section 4, where we examine the performance of our proposed method.
In Section 5, we study the comparative effect of metformin and sulfonylureas on weight gain
using The Health Improvement Network (THIN) database.
2. SETTINGS AND NOTATIONS
For simplicity we focus on observational studies with three treatment options A, B, and C. We
assume that we are only interested in comparing the effect of treatment A with B. We use small
letters to refer to the possible values of the corresponding capital letter random variable. Let Z be
3a binary instrumental variable where Z ∈ {A,B} such as provider preference. Z = A means that
the IV predisposes the patient to receive treatment level A among the options A and B, and Z = B
means that the IV predisposes the patient to receive treatment level B among the options A and
B; e.g., in Brookhart et al. (2006) study, if A denotes Cox-2 inhibitor and B denotes nonselective
NSAID, Z = A if the patient’s physician last prescription to a patient prescribed an NSAID was
a Cox-2 inhibotor and Z = B if it was a nonselective NSAID. Let D(z) be the potential treatment
assigned given Z = z, where D(z) ∈ {A,B,C}, i.e., D(A) is the treatment that would be received
if the IV was A. The potential outcomes are Y (z,d) for Z = z and D= d, i.e., Y (A,B) is the outcome
that would be observed if the IV was A and the treatment level was B. The observed treatment
and outcome are D= DZ and Y = Y Z,D
Z
, respectively.
Frangakis and Rubin (2002) developed a basic principal strata (PS) framework which stratifies
subjects based on their potential assigned treatments. In our setting, we can classify subjects into
the following 9 principal strata: S1) always B taker, S2) always A taker, S3) always C taker, S4)
subjects who would comply with their value of instrumental variable, i.e., D(A) = A, D(B) = B,
S5) subjects who would take B if Z = B and would take C if Z = A, S6) subjects who would take
C if Z = B and would take A if Z = A, S7) subjects who would take A if Z = B and would take
B if Z = A, S8) subjects who would take B if Z = A and would take C if Z = B, and S9) subjects
who would take A if Z = B and would take C if Z = A. We denote the proportions in the basic
principal strata as piS..
We assume that the IV satisfies the following standard assumptions (Angrist et al., 1996): 1)
stable unit treatment value assumption, 2) The IV is independent of unmeasured confounders,
potential outcomes and potential treatment received, 3) the IV affects the treatment but has no
direct effect on the outcome. This assumption is known to as the exclusion restriction (ER)
assumption. Under the exclusion restriction, we let Y d be the potential outcome if treatment d is
received which equalY z=0,d =Y z=1,d , and 4) the IV is independent of the pretreatment covariates,
potential outcome and potential treatments. Furthermore, we assume two types of monotonicity
assumptions: 5) monotonicity I: there is no defiers (i.e., p(D(A) 6= A,D(B) 6= B) = 0) and 6)
monotonicity II: there is no one who would take B if Z = A but take C if Z = B and no one who
would take C if Z = A but take A if Z = B. Note that monotonicity assumptions 5 & 6 reduce the
number of principal strata to 6. The parameter of interest is defined as
θ = E[YA−YB|PS= S4].
3. IV SELECTION BIAS
We show in this manuscript that IV analysis methods may not result in an unbiased treatment
effect if applied on a data set in which units are preselected based on their received treatments.
A standard IV analysis of patients on the subset of patients for whom D = A or B is essentially
a comparison of the Z = A vs. Z = B patients on this subset. If Z = A has a different effect on
whether D=C than Z = B, then there will be selection bias. For example, patients who are in a
more severe stages of the disease may be treated with treatment D =C and therefore have less
chance to be observed in the sample; if doctors who prefer drug A (Z = A) are more likely to
use treatment C with severe patients than doctors who prefer drug B (Z = B), then there will be
selection bias. Another scenario where such selection bias might arise is that treatmentC is more
likely to be offered if some complications are present and doctors who prefer drug A are more
likely to treat a patient with complications with drug C than doctors who prefer drug B.
The challenge is that θ is not identifiable using the observed data when there is selection bias.
This is due to the fact that the observed outcomes of Y |Z,D is a mixture of potential outcomes
4from principal strata. Let fA(y) be the density of outcome for a patient who received D= A when
assigned to Z = A (i.e., fA(y) = f (y|D= A,Z = A). Then
fA(y) = γS2A f
S2
A (y)+ γ
S4
A f
S4
A (y)+ γ
S6
A f
S6
A (y),
where γS.A =
piS.
piS2+piS4+piS6 and f
S.
A (y) is the density function of the outcome for subjects in principal
stratum S. with D= A. The density f S2A (y) and f
S6
A (y) can be written as
f S2A (y) =
p(D(B) = A|D(A) = A,Y (A) = y) fA(y)
p(D(B) = A|D(A) = A)
f S6A (y) =
p(D(B) =C|D(A) = A,Y (A) = y) fA(y)
p(D(B) =C|D(A) = A)
Thus,
f S4A (y) =
[1− p(D(B) =C|D(A) = A,Y (A) = y)− p(D(B) = A|D(A) = A,Y (A) = y)] fA(y)
γS4A
(1)
Similarly, let fB(y) be the density of outcome for a patient who received D = B when assigned
to Z = B. Then
fB(y) = γS1B f
S1
B (y)+ γ
S4
B f
S4
A (y)+ γ
S5
B f
S5
B (y),
where γS.B =
piS.
piS1+piS4+piS5 and f
S.
B (y) is the density function of the outcome for subjects in principal
stratum S. with D= B. Also,
f S1B (y) =
p(D(A) = B|D(B) = B,Y (A) = y) fA(y)
p(D(A) = B|D(B) = B)
f S5B (y) =
p(D(A) =C|D(B) = B,Y (B) = y) fB(y)
p(D(A) =C|D(B) = B)
Thus,
f S4B (y) =
[1− p(D(A) =C|D(B) = B,Y (B) = y)− p(D(A) = B|D(B) = B,Y (B) = y)] fB(y)
γS4B
. (2)
The mixture proportions γS.A and γ
S.
B are unknown and need to be estimated using the observed
data. However, the strata proportions piS. are not identifiable using the proportions in the observ-
able (D,Z) strata, because
p(D= A|Z = A) = piS2+piS4+piS6
p(D= A|Z = B) = piS2
p(D= B|Z = A) = piS1
p(D= B|Z = B) = piS1+piS4+piS5
p(D=C|Z = B) = piS3+piS6
p(D=C|Z = A) = piS3+piS5, (3)
does not have a unique solution. Also, the density functions f S4A (y) and f
S4
B (y) are not identifi-
able using the observed data because p(D(B) = A|D(A) = A,Y (A) = y), p(D(B) = C|D(A) =
A,Y (A) = y), p(D(A) = B|D(B) = B,Y (B) = y) and p(D(A) =C|D(B) = B,Y (B) = y) are un-
known. So we assume logit models for these probabilities and perform the sensitivity analysis
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Fig. 1: Causal diagram. Conditioning on subjects with R= 1 leads to a bias treatment effect esti-
mate in the left figure. Assumptions A.1 and A.2 hold for the center and right figure, respectively.
based on these models;
p(D(B) = B|D(A) = A,Y (A) = y) = wA(y;α0A,α1A) = e
α0A+α1Ay
1+ eα0A+α1Ay
(4)
p(D(A) = A|D(B) = B,Y (B) = y) = wB(y;α0B,α1B) = e
α0B+α1By
1+ eα0B+α1By
. (5)
Note that for any fixed (α1A,α1B), (α0A,α0B) can be determined since
∫
f S4A (y)dy = 1 and∫
f S4B (y)dy = 1. Therefore, the parameter of interest θ can be estimated using the four dimen-
sional sensitivity parameter (γS4A ,γ
S4
B ,α1A,α1B).
Remark. If it is plausible to assume that at least one of the principal strata piS3 , piS5 or piS6 is
empty, we can reduce the dimension of the sensitivity parameters to two by estimating γS4A and
γS4B using the observed data.
3·1. No Selection Bias
Let R be a binary variable which is 1 if a patient is assigned to one of the treatments of interest
and 0 otherwise. Under either of the following two conditions, the treatment effect is identifiable
when we have access to the entire data (i.e., data includes patients who have received treatment
C as well as A and B):
A.1 p(R= 0|Z,U,X)= p(R= 0|U,X)where X andU are measured and unmeasured confounders,
respectively.
A.2 p(R= 0|Z,U,X) = p(R= 0|Z,X).
Assumption A.1 implies that the IV is unrelated to the patient’s selection. In other words, a
patient would have the same chance of being selected for both values of the IV. A.2 means that
the selection probability is independent of the unmeasured confounders given the instrumental
variable and measured confounders. Figure 1 depicts the association between different variables.
The left plot presents a scenario in which analyzing the preselected data will cause bias because
conditioning on R will open the path Z→ R→U→Y which violates one of the IV assumptions.
This path is closed under either of assumptions A.1 or A.2 as shown in the center and right plots,
respectively.
Under either of assumptions A.1 or A.2, the treatment effect can be identified. Specifically,
under assumption A.1, the principal strata S5 and S6 does not exist. Thus
E[Y |Z = A,D= A] = γS2E[YA|PS= S2]+ γS4E[YA|PS= S4]
E[Y |Z = B,D= B] = γS1E[YB|PS= S1]+ γS4E[YB|PS= S4]
E[Y |Z = A,D= B] = γS1E[YB|PS= S1]
E[Y |Z = B,D= A] = γS2E[YA|PS= S2].
6These equations can be used to identify θ = E[YA−YB|PS = S4]. Also, under assumption A.2,
θ can be estimated using the following three-step procedure:
Step1. Using the entire data, estimate ϖ = p(R= 1|X,Z) by postulating a logit model on S.
Step2. Include patients who have been assigned to either treatments A or B.
Step3. Estimate the treatment effect θ using 2SLS IV approach. At each stage fit a weighted least
square where weights are ϖ̂ .
Fitting weighted least squares accounts for the selection procedure and hence avoids the bias
by creating a pseudo-population in which there is no association between (X,Z) and R.
3·2. Inference Procedure
Let YA= (YA1,YA2, ...,YAnA) and YB= (YB1,YB2, ...,YBnB) denote the outcome of patients whose
received treatment matches their IV value for Z = A and Z = B, respectively. We assume that
samples are independent within and between each IV group and identically distributed within
each group.
For any fixed (γS4A ,γ
S4
B ,α1A,α1B), (α̂0A, α̂0B) is defined as a solution to∫ −∞
−∞
eα0A+α1Ay
1+ eα0A+α1Ay
dF̂A(y) = γS4A∫ −∞
−∞
eα0B+α1By
1+ eα0B+α1By
dF̂B(y) = γS4B
where F̂A(y) and F̂B(y) are empirical distributions calculated from the observed samples YA and
YB. These equations can be solved using a one dimensional grid search on real line.
We estimate the treatment effect θ by
θ̂ =
[
1
γS4A nA
nA
∑
j=1
yA jwA(yA j; α̂0A,α1A)
]
−
[
1
γS4B nB
nB
∑
j=1
yB jwB(yB j; α̂0B,α1B)
]
.
where wA(.) and wB(.) are defined in (4) and (5). By bootstrap sampling from YA and YB, we
can estimate the standard error of θ̂ as the standard error of the estimated treatment effect from
each bootstrapped sample.
4. SIMULATION STUDIES
Through simulations we examine the performance of our proposed sensitivity analysis assum-
ing known and unknown (γS4A ,γ
S4
B ). We assume two scenarios with the following principal strata
proportions: Scenario 1:r Scenario 1: piS1 = piS2 = piS3 = piS5 = 0.1, piS4 = 0.3 and piS6 = 0.3 which gives us (γS4A ,γS4B ) =
(0.30.7 ,
0.3
0.5).r Scenario 2: piS1 = piS2 = piS3 = 0.1, piS4 = 0.3, piS5 = 0.4 and piS6 = 0.0 which gives us
(γS4A ,γ
S4
B ) = (
0.2
0.3 ,
0.2
0.7).
The true amount of selection bias is determined by the parameters α1A and α1B in (4) and (5),
respectively. The outcome of individuals with D = A and Z = A are generated from a normal
distribution with mean 2.5 and standard error 2 (i.e., fA(y) = N(2.5,2)). Also, the outcome of
individuals with D = B and Z = B are generated from a normal distribution with mean µ and
standard error 2 (i.e., fB(y) =N(µ,2)). For each set of (α1A,α1B), the parameter µ is determined
7Fig. 2: Simulation study: Sensitivity analysis of θ = 0.80 when γS4A and γ
S4
B are known. The
true sensitivity parameter values are (α1A,α1B) = (1,2). The darker area in left panel indicates
the smaller bias and the darker area in the right panel shows the region in which the bias is not
significant at 5%. The first and second rows represent Scenario 1 and 2, respectively.
such that the true treatment effect among compliers is θ = 0.00, 0.50 and 0.80. We generate
samples using rejection sampling from densities f S4B (y) and f
S4
B (y) according to (1) and (2),
respectively.
Table 1 presents the statistical power of detecting the true treatment effect θ = 0.0, 0.50,
and 0.80 based on 500 datasets of sizes n=500 with (α1A,α1B) = (1,2), (1,1) and (0,0). The
nominal type-I error rate is 5%. For both scenarios when the true amount of selection bias
is presumed, the empirical and nominal sizes are close. In general, the empirical sizes are in-
flated when the selection bias parameters are not set correctly. For some of the combinations of
the true and presumed sensitivity parameter values the power and type-I error rate are much
higher than the nominal one which is caused by the overestimation of the treatment effect.
Also, in scenario 2, when there is no selection bias (i.e., true (α1A,α1B) = (0,0)) and we pre-
sumed (α1A,α1B) = (1,1) the power is very low because of the underestimation of the treat-
ment effect. Table 2 shows the bias (0.80− θ̂ ), standard error and mean squared error of the
treatment effect estimation for different combinations of the true and presumed sensitivity pa-
rameters when the true treatment effect θ = 0.80. This table highlights the over- and underes-
timation phenomenon discussed earlier. Specifically, when the true sensitivity parameters are
(α1A,α1B) = (1,2), presuming (α1A,α1B) = (0,2) will result in underestimating the counterfac-
tual mean outcome E[YA|PS = S4]. This is because when we set the presumed α1A less than the
true value, the larger outcomes are less likely to be a complier among patients with D= Z = A.
In other words it will shift the distribution of this compliers to left. Similarly when the presumed
α1A more than the true value, E[YA|PS = S4] will be overestimated (See rows 3 and 4 in Table
2).
Figure 2 shows how the treatment effect estimate changes by the sensitivity parameters when
the true (α1A,α1B) = (1,2) and θ = 0.80. The darker area in left panel of Figure 2 indicates
8Fig. 3: Simulation study (Scenario 1): Sensitivity analysis of θ = 0.80. Sensitivity parameters
are (γS4A ,γ
S4
B ,α1A,α1B). The darker area in left panel indicates the smaller bias and the darker
area in the right panel shows the region in which the bias is not significant at 5%. The true vector
of sensitivity parameters are (γS4A ,γ
S4
B ,α1A,α1B) =
(3
7 ,
3
5 ,1,2
)
.
the smaller bias and the darker area in the right panel shows the region in which the bias is not
significant at 5% (i.e., the confidence interval for (0.80− θ̂) contains zero). See also Table 2.
4·1. Unknown (γS4A ,γS4B )
In this case our sensitivity parameter space is (γS4A ,γ
S4
B ,α1A,α1B). Figures 3 and 4 present the
bias in the treatment effect estimation for different values of the presumed sensitivity parameters
based on scenarios 1 and 2, respectively. In these figures the true (γS4A ,γ
S4
B ,α1A,α1B) = (
3
7 ,
3
5 ,1,2)
and (γS4A ,γ
S4
B ,α1A,α1B) = (
2
3 ,
2
7 ,1,2) in scenarios 1 and 2, respectively. Also the true treatment
effect is θ = 0.80. The darker area in the left panel shows the region in the sensitivity parameter
space in which the bias is smaller and right panel shows the area in which the bias is not signifi-
cant based on 500 samples (i.e., the confidence interval for (0.80− θ̂) contains zero). The shape
9Fig. 4: Simulation study (Scenario 2): Sensitivity analysis of θ = 0.80. Sensitivity parameters
are (γS4A ,γ
S4
B ,α1A,α1B). The darker area in left panel indicates the smaller bias and the darker
area in the right panel shows the region in which the bias is not significant at 5%. The true vector
of sensitivity parameters are (γS4A ,γ
S4
B ,α1A,α1B) =
(2
3 ,
2
7 ,1,2
)
.
of the area which leads to an unbiased estimate changes by the value of the presumed (γS4A ,γ
S4
B )
and, in general, when the presumed values of (γS4A ,γ
S4
B ) are far from the true values, the unbiased
area is small which means it would be less likely to find an unbiased treatment effect estimate
using sensitivity analysis (see also Table 4 in Appendix A). We have tabulated the power and
type-I error rate for different values of the presumed sensitivity parameters in Table 3. This Ta-
ble summarizes the result for three different values of the true treatment effect θ = 0.00,0.50,
and 0.80. The nominal type-I error rate is 5%.
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Table 1: Simulation study: Power analysis of θ = 0.00,0.50 and 0.80 when γS4A and γ
S4
B are
known.
Scenario 1 Scenario 2
True (α1A,α1B) Presumed (α1A,α1B) 0.00 0.50 0.80 0.00 0.50 0.80
(1,2) (1,2) 0.04 0.60 0.91 0.04 0.52 0.86
(1,2) (1,1) 0.12 0.81 0.98 0.22 0.88 0.97
(1,2) (0,0) 0.16 0.36 0.78 0.99 1.00 1.00
(1,1) (1,1) 0.05 0.58 0.91 0.05 0.48 0.85
(1,1) (2,2) 0.08 0.71 0.95 0.10 0.24 0.61
(1,1) (0,0) 0.35 0.05 0.40 0.90 1.00 1.00
(0,0) (0,0) 0.04 0.61 0.92 0.05 0.60 0.94
(0,0) (1,0) 1.00 1.00 1.00 0.80 1.00 1.00
(0,0) (1,1) 0.34 0.96 1.00 0.81 0.00 0.03
Table 2: Simulation study: Sensitivity analysis of θ = 0.80 when γS4A and γ
S4
B are known. Bias=
0.80− θ̂ .
Scenario 1 Scenario 2
True (α1A,α1B) Presumed (α1A,α1B) Bias S.D. MSE Bias S.D. MSE
(1,2) (1,2) -0.01 0.28 0.08 0.01 0.30 0.09
(1,2) (1,1) -0.22 0.29 0.14 -0.38 0.32 0.25
(1,2) (0,2) 1.38 0.25 1.97 0.81 0.29 0.74
(1,2) (1,0) -1.18 0.25 1.43 -2.17 0.28 4.82
(1,2) (0,0) 0.21 0.23 0.10 -1.34 0.25 1.86
(1,1) (1,1) 0.00 0.28 0.08 -0.01 0.30 0.10
(1,1) (1,2) 0.19 0.28 0.11 0.39 0.31 0.26
(1,1) (0,2) 1.58 0.27 2.58 1.17 0.30 1.49
(1,1) (1,0) -0.98 0.26 1.02 -1.77 0.28 3.20
(1,1) (0,0) 0.41 0.23 0.23 -0.95 0.27 0.98
5. APPLICATION TO REAL DATA
The Health Improvement Network (THIN) is a large database, which contains the electronic
medical record of more than 11 million patients. The data contains longitudinal measurements
of diagnostic and prescription data and baseline characteristics collected from over 500 general
practices in the UK. We are interested in assessing the effect of metformin and sulfonylureas
on body mass index (BMI, calculated as mass in kilograms divided by the square of height in
meters) among diabetic patients. Our focus is on patients who are taking these treatments as an
initial treatment and the BMI is measured two years after treatment initiation. In our analysis we
coded metformin and sulfonylureas as A and B, respectively.
In the modern era, metformin is universally acknowledged as the appropriate first-line medica-
tion for diabetes type 2 except where contraindicated (Nathan et al., 2009). While this dominance
was being established in the late 1990s and early 2000s, sulfonylureas were the competing first
line agent. During that time the prevalence of metformin use in clinical practice rose very quickly,
at the expense of sulfonylureas.
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Table 3: Simulation study: Power analysis of θ = 0.00,0.50 and 0.80. The true vector of sen-
sitivity parameters in scenario 1 and 2 are (γS4A ,γ
S4
B ,α1A,α1B) = (
3
7 ,
3
5 ,1,2), and (
2
3 ,
2
7 ,1,2), re-
spectively.
Presumed Scenario 1 Scenario 2
(γS4A ,γ
S4
B ,α1A,α1B) 0.00 0.50 0.80 0.00 0.50 0.80
(0.3,0.6,1,2) 0.38 0.90 0.98 1.00 1.00 1.00
(0.3,0.6,0,2) 1.00 0.00 0.00 0.07 0.73 0.96
(0.3,0.6,1,0) 1.00 1.00 1.00 1.00 1.00 1.00
(0.3,0.6,0,0) 0.12 0.35 0.80 1.00 1.00 1.00
(0.5,0.5,1,2) 0.40 0.08 0.38 0.93 1.00 1.00
(0.5,0.5,0,2) 1.00 0.00 0.00 0.04 0.40 0.75
(0.5,0.5,1,0) 0.96 1.00 1.00 1.00 1.00 1.00
(0.5,0.5,0,0) 0.10 0.29 0.76 1.00 1.00 1.00
(0.2,0.8,1,2) 0.98 1.00 1.00 1.00 1.00 1.00
(0.2,0.8,0,2) 0.94 0.00 0.05 0.61 1.00 1.00
(0.2,0.8,1,0) 1.00 1.00 1.00 1.00 1.00 1.00
(0.2,0.8,0,0) 0.06 0.24 0.65 1.00 1.00 1.00
(0.7,0.2,1,2) 1.00 0.00 0.00 0.30 0.08 0.32
(0.7,0.2,0,2) 1.00 0.00 0.00 0.98 0.00 0.00
(0.7,0.2,1,0) 0.65 0.99 1.00 1.00 1.00 1.00
(0.7,0.2,0,0) 0.12 0.39 0.87 1.00 1.00 1.00
The dynamic aspect of the preference justifies the use of provider preference as an IV. We
define the preference as a time-varying quantity such that for each practice ID, the IV is defined
as an average of metformin use during each two year timeframe from 1998 to 2012. We assign
Z = A if the average is more than 50% and B otherwise. Thus, a particular practice ID may have
Z = A for one period of time and B for the other.
Our data includes patients who have been assigned to medications other than metformin or sul-
fonylureas as an initial therapy. Figure 5 presents the sensitivity analysis for the estimation of the
treatment effect of interest based on a four dimensional sensitivity parameter (γS4A ,γ
S4
B ,α1A,α1B).
The parameter α1A identifies the probability that a patient with a particular value of BMI would
have taken D= B if Z = B (i.e., seeing a physician with sulfonylureas preference) given that she
has taken D = A with Z = A (i.e., seeing a physician with metformin preference). The parame-
ter α1B has a similar interpretation and the parameter γS4A (γ
S4
B ) is defined as a chance of being
a complier for patients who have been assigned to Z = A(B) and have taken D = A(B). Since
the association of sulfonylureas with weight gain is known it makes sense to assume that the
true value of the parameter α1A should be negative and α1B should be positive. Also on average
patients who have taken sulfonylureas (D= B) given Z = B are more likely to be compliers com-
pare with those who have taken metformin (D= A) given Z = A. This means that it is very likely
that γS4A < γ
S4
B .
The range of the treatment effect estimate varies by different choices of γS4A and γ
S4
B . Specifi-
cally, for γS4A = 0.2 and γ
S4
B = 0.6, the treatment effect lies in [−0.5,1]; while for γS4A = 0.5 and
γS4B = 0.3, it lies in [−0.7,0.5]. Based on our sensitivity analysis, it is unlikely that metformin
be associated with increase in BMI and a large negative effect (i.e., E[YA−YB|PS= S4]) is also
unlikely because it requires very small and large values of α1A and α1B, respectively. Hence, if
anything, the treatment effect of interest should lie in [−0.6,−0.1].
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Fig. 5: THIN data: Sensitivity analysis for comparing the effect of metformin with sulfonylureas
on BMI. Numbers on the plot present treatment effect estimates.
6. DISCUSSION
This manuscript shows that IV analysis methods may fail to provide an unbiased estimate
of treatment effects when analyzing data in which subjects are selected based on their received
treatment. Specifically, this selection bias happens if the chance of including patients in the pre-
selected data varies based on their IV value and/or some unmeasured confounders. For example,
suppose we are interested in studying the comparative effect of treatment A and B while there is
a third choice of treatment C. Suppose patients with more severe stages of the disease are more
likely to be treated with C if seeing a doctor with A preference. Then if we analyzed a data that
only includes patients who have received treatment A or B, severe cases will be under represented
among patients who have seen doctors with A preference. This means that in the preselected data,
the IV is associated with an unmeasured confounder which makes the IV invalid and results in a
biased treatment effect estimate.
Within the principal strata framework, we develop a sensitivity analysis that can be used to
estimate the treatment effect among compliers as a function of a vector of sensitivity parameters.
Specifically, the sensitivity parameters are used to identify the probability of being a complier
given the IV value, received treatment and the observed outcome. The dimension of the sensi-
tivity parameter can be reduced if it is plausible to assume that there is no always C takers. This
is because the proportions in the principal strata are identifiable which means γS4A and γ
S4
B can be
estimated using the observed data.
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Table 4: Simulation study: Sensitivity analysis of θ = 0.80. The true vector of sensitivity pa-
rameters in scenario 1 and 2 are (γS4A ,γ
S4
B ,α1A,α1B) = (
3
7 ,
3
5 ,1,2), and (
2
3 ,
2
7 ,1,2), respectively.
Scenario 1 Scenario 2
Presumed (γS4A ,γ
S4
B ,α1A,α1B) Bias S.D. MSE Bias S.D. MSE
(0.3,0.6,1,2) -0.37 0.29 0.22 -1.92 0.34 3.79
(0.3,0.6,0,2) 1.37 0.24 1.95 -0.18 0.30 0.12
(0.3,0.6,1,0) -1.54 0.27 2.45 -3.07 0.34 9.55
(0.3,0.6,0,0) 0.23 0.24 0.11 -1.32 0.27 1.83
(0.5,0.5,1,2) 0.46 0.26 0.28 -1.09 0.29 1.28
(0.5,0.5,0,2) 1.65 0.26 2.80 0.11 0.27 0.08
(0.5,0.5,1,0) -0.95 0.27 1.04 -2.57 0.28 6.72
(0.5,0.5,0,0) 0.20 0.23 0.09 -1.35 0.26 1.89
(0.2,0.8,1,2) -1.22 0.31 1.59 -2.76 0.39 7.80
(0.2,0.8,0,2) 0.87 0.25 0.81 -0.69 0.27 0.55
(0.2,0.8,1,0) -1.86 0.29 3.54 -3.42 0.36 11.88
(0.2,0.8,0,0) 0.23 0.23 0.11 -1.32 0.25 1.79
(0.7,0.2,1,2) 1.98 0.34 4.03 0.44 0.32 0.30
(0.7,0.2,0,2) 2.72 0.33 7.54 1.20 0.32 1.53
(0.7,0.2,1,0) -0.55 0.24 0.36 -2.09 0.27 4.45
(0.7,0.2,0,0) 0.18 0.25 0.10 -1.34 0.26 1.88
APPENDIX
In this Appendix, we present the supplementary materials.
APPENDIX: A
Table 4 shows the bias (0.80− θ̂ ), standard error and mean squared error of the treatment effect esti-
mation for different combinations of the true and presumed sensitivity parameters when the true treatment
effect θ = 0.80.
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